Trends in pioglitazone use among US adults with type 2 diabetes and suspected non-alcoholic fatty liver disease.
BackgroundWe aimed to estimate population-based trends in prevalence of coexisting type 2 diabetes (T2D) and suspected non-alcoholic fatty liver disease (NAFLD) and pioglitazone use among US adults.Research design and methodsWe conducted a cross-sectional analysis of the National Health and Nutrition Examination Survey from 2003-2016. We included people aged ≥18 years who had HbA1C >6.4%, fasting plasma glucose >125 mg/dL, or were told they had diabetes by a doctor. Suspected NAFLD was defined using hepatic steatosis index of >36. Prevalence was estimated for each 2-year survey cycle. Trends were analyzed using logistic regression, accounting for the complex survey design.ResultsTotal sample size was 40,323 US adults, of which 5,690 had T2D. Age-adjusted prevalence of T2D with NAFLD increased from 5.6% in 2003-2004 to 6.8% in 2015-2016 (p-value <0.001). Pioglitazone use peaked at 20% in 2005-2006, then declined to 4.1% in 2013-2014. Patients with suspected NAFLD were not more likely to receive pioglitazone; 3.8% of patients received the drug in 2015-2016.ConclusionsThe prevalence of T2D with suspected NALFD increased among US adults, but pioglitazone use decreased significantly over 2003-2016. Our study suggested a missed opportunity to prevent a future epidemic of cirrhosis due to NAFLD in patients with T2D.